Stockscreener 앱 받기
141.12
1.45%
2.02
시간 외 거래:
141.08
-0.04
-0.03%
전일 마감가:
$139.10
열려 있는:
$138.68
하루 거래량:
427.64K
Relative Volume:
3.13
시가총액:
$2.72B
수익:
$152.42M
순이익/손실:
$45.24M
주가수익비율:
56.22
EPS:
2.51
순현금흐름:
$6.97M
1주 성능:
+11.19%
1개월 성능:
+23.71%
6개월 성능:
+20.25%
1년 성능:
+41.46%
1일 변동 폭
$137.37
$143.13
1주일 범위
$122.29
$143.13
52주 변동 폭
$90.29
$143.13
리간드 파마 Stock (LGND) Company Profile
명칭
Ligand Pharmaceuticals Inc
전화
858-550-7500
주소
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
LGND을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
141.12 | 2.45B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
리간드 파마 Stock (LGND) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-10 | 개시 | Stifel | Buy |
| 2024-10-03 | 개시 | Oppenheimer | Outperform |
| 2024-07-30 | 개시 | RBC Capital Mkts | Outperform |
| 2021-04-14 | 재개 | Stephens | Overweight |
| 2021-02-04 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-06 | 개시 | Barclays | Overweight |
| 2020-03-24 | 다운그레이드 | Argus | Buy → Hold |
| 2020-03-10 | 개시 | Guggenheim | Neutral |
| 2020-02-06 | 개시 | The Benchmark Company | Buy |
| 2019-09-19 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-03 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-06 | 재확인 | H.C. Wainwright | Buy |
| 2018-10-29 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2018-10-02 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-11 | 재확인 | Argus | Buy |
| 2018-08-17 | 개시 | Goldman | Neutral |
| 2018-08-08 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2018-06-21 | 개시 | Argus | Buy |
| 2017-12-27 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-05 | 재개 | H.C. Wainwright | Buy |
| 2016-10-05 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-05 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2016-03-11 | 개시 | Sidoti | Buy |
| 2016-03-03 | 개시 | H.C. Wainwright | Buy |
모두보기
리간드 파마 주식(LGND)의 최신 뉴스
What drives Ligand Pharmaceuticals Incorporated stock priceGame-changing capital returns - jammulinksnews.com
What analysts say about Ligand Pharmaceuticals Incorporated stockExceptional profit potential - jammulinksnews.com
Is Ligand Pharmaceuticals Incorporated a good long term investmentSuperior capital gains - jammulinksnews.com
Stifel reiterates Buy rating on Ligand Pharma stock at $143 price target - Investing.com Canada
Teacher Retirement System of Texas Has $534,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals stock hits 52-week high at 130.0 USD - Investing.com Australia
Ligand Pharmaceuticals stock hits 52-week high at 130.0 USD By Investing.com - Investing.com Nigeria
What makes Ligand Pharmaceuticals Incorporated stock price move sharplyHigh Yield Opportunities - Newser
How Ligand Pharmaceuticals Incorporated stock performs during market volatilityFree Real-Time Trading Opportunities - Newser
Why Ligand Pharmaceuticals Incorporated stock attracts strong analyst attentionFree Access to Community - Newser
Principal Financial Group Inc. Acquires 3,284 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Insider Sell Alert: John Kozarich Sells Shares of Ligand Pharmac - GuruFocus
Ligand Pharmaceuticals director Kozarich sells $116k in stock By Investing.com - Investing.com South Africa
Ligand Pharmaceuticals director Kozarich sells $116k in stock - Investing.com Australia
Amalgamated Bank Has $564,000 Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand earns $5 million milestone as partner launches molluscum treatment By Investing.com - Investing.com South Africa
Ligand Pharmaceuticals (LGND) Soars 2.11% on ZELSUVMI Launch, Milestone Payment - AInvest
Pelthos Therapeutics shares rise 1.27% in after-hours after commercial launch of ZELSUVMI™ and merger with Channel Therapeutics. - AInvest
Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts - Stocktwits
ZELSUVMI's FDA Approval: A Breakthrough for Pelthos and a Windfall for Ligand? - AInvest
ZELSUVMI Launch Positions Ligand Pharmaceuticals for Growth in a Booming Skin Care Market - AInvest
Ligand earns $5 million milestone as partner launches molluscum treatment - Investing.com
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI - MarketScreener
Ligand Pharmaceuticals Partner Pelthos Launches Molluscum Contagiosum Treatment Zelsuvmi - MarketScreener
Ligand (LGND) Advances with Successful Launch of ZELSUVMI Gel | - GuruFocus
Ligand Pharmaceuticals Partner Pelthos Therapeutics Launches ZELSUVMI™ for Molluscum Contagiosum Treatment - Quiver Quantitative
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™ - GlobeNewswire
Breakthrough: First-Ever At-Home Treatment for Molluscum LaunchesLigand Secures $5M Milestone Payment - Stock Titan
Pelthos Therapeutics shares surge 82.73% intraday after launching ZELSUVMI, the first FDA-approved at-home treatment for molluscum contagiosum. - AInvest
GAMMA Investing LLC Has $62,000 Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of “Buy” from Analysts - Defense World
Ligand’s LNHC concludes merger with CHRO - Yahoo Finance
Ligand Pharma Completes Merger Forming Pelthos Therapeutics - TipRanks
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics - The Manila Times
Pelthos Therapeutics to Launch ZELSUVMI™ for Molluscum Contagiosum in July 2025 Following Merger with Ligand Pharmaceuticals - Quiver Quantitative
Ligand completes merger, Pelthos to launch molluscum treatment - Investing.com
Ligand completes merger, Pelthos to launch molluscum treatment By Investing.com - Investing.com UK
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) added to Russell 2000 Growth-Defensive Index - MarketScreener
Ligand Pharmaceuticals: How a Biotech Royalty Model Drives Sustainable Growth - AInvest
Yousif Capital Management LLC Sells 181 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Handelsbanken Fonder AB Has $700,000 Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Wealth Enhancement Advisory Services LLC Takes $286,000 Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Cutaneous T-cell Lymphoma Market on Track for Major Expansion by 2034, According to DelveInsight | Innate Pharma, Galderma R&D, Kyowa Kirin, Citius Pharma, Soligenix, 4SC AG, oligenix, Ligand Pharma - Barchart.com
Rhumbline Advisers Has $6.04 Million Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals CLO Andrew Reardon sells $57,270 in shares By Investing.com - Investing.com India
Ligand Pharmaceuticals CLO Andrew Reardon sells $57,270 in shares - Investing.com Australia
3 Companies That May Be Trading Below Their Estimated Value - Yahoo Finance
Ligand Announces 2025 Investor Day in New York City | LGND Stock News - GuruFocus
Ligand Pharmaceuticals to Host Investor Day in New York City on December 9, 2025 - Nasdaq
Ligand Announces 2025 Investor Day in New York City - Bluefield Daily Telegraph
리간드 파마 (LGND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):